Mesa Laboratories Inc. (NASDAQ:MLAB) CFO John Sakys sold 1,000 shares of Mesa Laboratories stock in a transaction on Thursday, November 17th. The shares were sold at an average price of $127.14, for a total value of $127,140.00. Following the sale, the chief financial officer now directly owns 2,000 shares of the company’s stock, valued at approximately $254,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Mesa Laboratories Inc. (NASDAQ:MLAB) traded up 0.01% during midday trading on Monday, reaching $131.30. The company had a trading volume of 672 shares. The company has a market capitalization of $483.05 million, a price-to-earnings ratio of 45.84 and a beta of 0.65. The firm has a 50-day moving average price of $121.28 and a 200-day moving average price of $115.42. Mesa Laboratories Inc. has a 52 week low of $77.00 and a 52 week high of $134.34.

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 15th. Stockholders of record on Wednesday, November 30th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Monday, November 28th. This represents a $0.64 annualized dividend and a dividend yield of 0.49%. Mesa Laboratories’s dividend payout ratio (DPR) is 22.70%.

Separately, Zacks Investment Research lowered Mesa Laboratories from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 10th.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

5 Day Chart for NASDAQ:MLAB

Receive News & Stock Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related stocks with our FREE daily email newsletter.